Our Pursuit of a Robust Pipeline for Bleeding Conditions
Shire's relentless focus on bleeding conditions is evident in the investment we make into our research programs. In addition to our Research and Development pipeline, we support and collaborate on a number of studies that will enhance our understanding of the mechanism of—and risk factors for—inhibitor development.
Continuous Innovation in Haemophilia Management
Shire is making extensive life cycle investments to optimise use of prophylaxis and develop new technologies to meet the current and future needs of the global haemophilia community.
Shire is also supporting research designed to understand the aetiology of inhibitor development.
Exploring Management of Other Bleeding Conditions
Shire is also investing in the research of treatments for other bleeding conditions.